Brookline Capital Management Estimates CRSP Q3 Earnings

CRISPR Therapeutics AG (NASDAQ:CRSP) – Brookline Capital Management issued their Q3 2025 earnings per share estimates for shares of CRISPR Therapeutics in a research report issued on Tuesday, February 11th. Brookline Capital Management analyst L. Cann forecasts that the company will earn ($0.94) per share for the quarter. The consensus estimate for CRISPR Therapeutics’ current full-year earnings is ($5.08) per share. Brookline Capital Management also issued estimates for CRISPR Therapeutics’ Q4 2025 earnings at ($1.09) EPS.

Other equities analysts have also issued reports about the stock. JMP Securities restated a “market outperform” rating and issued a $86.00 price target on shares of CRISPR Therapeutics in a research report on Friday, December 20th. Needham & Company LLC reissued a “buy” rating and issued a $84.00 target price on shares of CRISPR Therapeutics in a report on Wednesday. HC Wainwright reaffirmed a “buy” rating and set a $65.00 price target on shares of CRISPR Therapeutics in a report on Thursday. StockNews.com upgraded CRISPR Therapeutics to a “sell” rating in a research report on Monday, December 30th. Finally, Chardan Capital cut their price target on CRISPR Therapeutics from $94.00 to $84.00 and set a “buy” rating for the company in a report on Thursday. Two investment analysts have rated the stock with a sell rating, nine have assigned a hold rating and eleven have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $75.56.

CRISPR Therapeutics Stock Performance

CRSP opened at $43.30 on Thursday. The firm has a market cap of $3.70 billion, a price-to-earnings ratio of -15.30 and a beta of 1.67. The firm’s 50-day simple moving average is $42.06 and its 200-day simple moving average is $46.25. CRISPR Therapeutics has a twelve month low of $36.52 and a twelve month high of $91.10.

CRISPR Therapeutics (NASDAQ:CRSP) last announced its quarterly earnings results on Tuesday, February 11th. The company reported ($0.44) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.15) by $0.71. CRISPR Therapeutics had a negative return on equity of 12.15% and a negative net margin of 118.13%.

Institutional Trading of CRISPR Therapeutics

A number of hedge funds have recently modified their holdings of CRSP. Sanctuary Advisors LLC bought a new stake in CRISPR Therapeutics in the second quarter valued at approximately $381,000. Exchange Traded Concepts LLC boosted its position in shares of CRISPR Therapeutics by 22.8% during the third quarter. Exchange Traded Concepts LLC now owns 19,192 shares of the company’s stock worth $902,000 after purchasing an additional 3,563 shares in the last quarter. Vontobel Holding Ltd. grew its holdings in shares of CRISPR Therapeutics by 3.7% in the 3rd quarter. Vontobel Holding Ltd. now owns 16,957 shares of the company’s stock valued at $797,000 after buying an additional 600 shares during the period. IQ EQ FUND MANAGEMENT IRELAND Ltd increased its position in shares of CRISPR Therapeutics by 56.4% in the 3rd quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 13,617 shares of the company’s stock valued at $640,000 after buying an additional 4,909 shares in the last quarter. Finally, nVerses Capital LLC acquired a new stake in CRISPR Therapeutics during the 3rd quarter worth $258,000. 69.20% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at CRISPR Therapeutics

In other news, CEO Samarth Kulkarni sold 15,000 shares of the business’s stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $55.10, for a total transaction of $826,500.00. Following the completion of the transaction, the chief executive officer now directly owns 181,540 shares in the company, valued at approximately $10,002,854. The trade was a 7.63 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 4.10% of the company’s stock.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.